Neurocrine Biosciences | NBIX - Trade Creditors


Neurocrine Biosciences reported $691.3M in Trade Creditors for its fiscal quarter ending in March of 2026.





Trade Creditors Change Date
AbbVie USD 3.59B 28.65B Dec/2025
Acadia Pharmaceuticals USD 44.57M 32.32M Jun/2026
Agios Pharmaceuticals USD 16.34M 2.6M Jun/2026
ALKERMES USD 142.86M 40.5M Jun/2026
Alnylam Pharmaceuticals USD 108.02M 18.61M Jun/2026
Amgen USD 2.86B 16.65B Jun/2026
Biogen USD 403.9M 45.4M Jun/2026
BioMarin Pharmaceutical USD 913.67M 120.52M Jun/2026
Cytokinetics USD 20.51M 4.2M Jun/2026
Enanta Pharmaceuticals USD 1.88M 63K Dec/2025
Exelixis USD 39.06M 14.91M Jun/2026
Gilead Sciences USD 645M 70M Mar/2026
Halozyme Therapeutics USD 23.61M 9.51M Jun/2026
Incyte USD 1.39B 1.16B Jun/2026
Ionis Pharmaceuticals USD 47.7M 21.67M Jun/2026
Nektar Therapeutics USD 10.03M 744K Mar/2026
Neurocrine Biosciences USD 691.3M 145.8M Mar/2026
Pfizer USD 4.58B 75M Jun/2026
Prothena USD 1.94M 2.36M Jun/2026
Regeneron Pharmaceuticals USD 1.16B 132.2M Jun/2026
Repligen USD 33.23M 1.42M Jun/2026
Rigel Pharmaceuticals USD 3.85M 3.44M Sep/2025
Sarepta Therapeutics USD 50.98M 19.39M Jun/2026
Teva Pharmaceutical Industries USD 2.72B 125M Jun/2026
Ultragenyx Pharmaceutical USD 39M 3M Jun/2026
Vertex Pharmaceuticals USD 3.61B 135M Jun/2026